How important is NK alloreactivity and KIR in allogeneic transplantation?

Best Practice and Research: Clinical Haematology

Volumn 29, Issue 4, 2016, Pages 351-358

  Shaffer, Brian C ^a,b   Hsu, Katharine C ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute myelogenous leukemia; Allo HCT; Allogeneic hematopoietic cell transplantation; Alloreactivity; AML; Graft versus host disease; Graft versus leukemia; GVHD; GVL; Killer Ig like receptors; KIR; Natural killer; NK

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE MYELOID LEUKEMIA; ALLELISM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ALLOTRANSPLANTATION; ALLOTYPE; CANCER RECURRENCE; EFFECTOR CELL; GENETIC VARIABILITY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HLA TYPING; HUMAN; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; ALLOGRAFT; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; TRANSPLANTATION;

ALLOGRAFTS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; RECEPTORS, KIR;

EID: 84997674116     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2016.10.010     Document Type: Review

References (56)

1. [1] Saber, W., Opie, S., Rizzo, J.D., Zhang, M.J., Horowitz, M.M., Schriber, J., Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 119 (2012), 3908–3916.
2. [2] Schmid, C., Labopin, M., Nagler, A., Bornhauser, M., Finke, J., Fassas, A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25 (2007), 4938–4945.
3. [3] Campbell, K.S., Hasegawa, J., Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 132 (2013), 536–544.
4. [4] Velardi, A., Ruggeri, L., Mancusi, A., Burchielli, E., Perruccio, K., Aversa, F., et al. Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol 30 (2008), 489–503.
5. [5] Shilling, H.G., McQueen, K.L., Cheng, N.W., Shizuru, J.A., Negrin, R.S., Parham, P., Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 101 (2003), 3730–3740.
6. [6] Petersen, S.L., Ryder, L.P., Bjork, P., Madsen, H.O., Heilmann, C., Jacobsen, N., et al. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors. Bone Marrow Transpl 32 (2003), 65–72.
7. [7] Yokoyama, W.M., Altfeld, M., Hsu, K.C., Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy. Biol Blood Marrow Transpl 16 (2010), S97–S105.
8. [8] Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M.R., et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118 (2011), 3273–3279.
9. [9] Bachanova, V., Burns, L.J., McKenna, D.H., Curtsinger, J., Panoskaltsis-Mortari, A., Lindgren, B.R., et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59 (2010), 1739–1744.
10. [10] Geller, M.A., Cooley, S., Judson, P.L., Ghebre, R., Carson, L.F., Argenta, P.A., et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13 (2011), 98–107.
11. [11] Kumar, V., George, T., Yu, Y.Y., Liu, J., Bennett, M., Role of murine NK cells and their receptors in hybrid resistance. Curr Opin Immunol 9 (1997), 52–56.
12. [12] Storkus, W.J., Alexander, J., Payne, J.A., Dawson, J.R., Cresswell, P., Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci USA 86 (1989), 2361–2364.
13. [13] Lanier, L.L., NK cell recognition. Annu Rev Immunol 23 (2005), 225–274.
14. [14] Anfossi, N., Andre, P., Guia, S., Falk, C.S., Roetynck, S., Stewart, C.A., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006), 331–342.
15. [15] Yu, J., Heller, G., Chewning, J., Kim, S., Yokoyama, W.M., Hsu, K.C., Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 179 (2007), 5977–5989.
16. [16] Tarek, N., Le Luduec, J.B., Gallagher, M.M., Zheng, J., Venstrom, J.M., Chamberlain, E., et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest 122 (2012), 3260–3270.
17. [17] Jonsson, A.H., Yokoyama, W.M., Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 101 (2009), 27–79.
18. [18] Yokoyama, W.M., Kim, S., Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 214 (2006), 143–154.
19. [19] Hsu, K.C., Keever-Taylor, C.A., Wilton, A., Pinto, C., Heller, G., Arkun, K., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105 (2005), 4878–4884.
20. [20] Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999), 333–339.
21. [21] Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002), 2097–2100.
22. [22] Giebel, S., Locatelli, F., Lamparelli, T., Velardi, A., Davies, S., Frumento, G., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003), 814–819.
23. [23] Hsu, K.C., Gooley, T., Malkki, M., Pinto-Agnello, C., Dupont, B., Bignon, J.D., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transpl 12 (2006), 828–836.
24. [24] Hsu, K.C., Liu, X.R., Selvakumar, A., Mickelson, E., O'Reilly, R.J., Dupont, B., Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 169 (2002), 5118–5129.
25. [25] Carrington, M., Martin, M.P., The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 298 (2006), 225–257.
26. [26] Hsu, K.C., Chida, S., Geraghty, D.E., Dupont, B., The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 190 (2002), 40–52.
27. [27] Parham, P., Moffett, A., Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 13 (2013), 133–144.
28. [28] Cooley, S., Trachtenberg, E., Bergemann, T.L., Saeteurn, K., Klein, J., Le, C.T., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113 (2009), 726–732.
29. [29] Cooley, S., Weisdorf, D.J., Guethlein, L.A., Klein, J.P., Wang, T., Marsh, S.G., et al. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192 (2014), 4592–4600.
30. [30] Venstrom, J.M., Pittari, G., Gooley, T.A., Chewning, J.H., Spellman, S., Haagenson, M., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367 (2012), 805–816.
31. [31] Sivori, S., Carlomagno, S., Falco, M., Romeo, E., Moretta, L., Moretta, A., Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 117 (2011), 4284–4292.
32. [32] Chewning, J.H., Gudme, C.N., Hsu, K.C., Selvakumar, A., Dupont, B., KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 179 (2007), 854–868.
33. [33] Venstrom, J.M., Gooley, T.A., Spellman, S., Pring, J., Malkki, M., Dupont, B., et al. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 115 (2010), 3162–3165.
34. [34] Mancusi, A., Ruggeri, L., Urbani, E., Pierini, A., Massei, M.S., Carotti, A., et al. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. Blood 125 (2015), 3173–3182.
35. [35] Boudreau, J.E., Le Luduec, J.B., Hsu, K.C., Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles. PLoS One, 9, 2014, e99543.
36. [36] Boudreau, J.E., Mulrooney, T.J., Le Luduec, J.B., Barker, E., Hsu, K.C., KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV. J Immunol 196 (2016), 3398–3410.
37. [37] Martin, M.P., Qi, Y., Gao, X., Yamada, E., Martin, J.N., Pereyra, F., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 39 (2007), 733–740.
38. [38] Giglio, F., Gooley, T.A., Venstrom, J.M., Gallagher, M.M., Hou, L., Hurley, C.K., et al. Donor KIR3DL1 and HLA-B allotypes control leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood (ASH Annu Meet), 120, 2012, 349 [abstr].
39. [39] Forlenza, C.J., Boudreau, J.E., Zheng, J., Le Luduec, J.B., Chamberlain, E., Heller, G., et al. KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma. J Clin Oncol 34 (2016), 2443–2451.
40. [40] Bari, R., Bell, T., Leung, W.H., Vong, Q.P., Chan, W.K., Das, G.N., et al. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 114 (2009), 5182–5190.
41. [41] Bari, R., Rujkijyanont, P., Sullivan, E., Kang, G., Turner, V., Gan, K., et al. Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 31 (2013), 3782–3790.
42. [42] Bari, R., Schell, S., Tuggle, M., Leung, W., An improved method with high specificity for KIR2DL1 functional allele typing. Lab Med 46 (2015), 207–213.
43. [43] Frazier, W.R., Steiner, N., Hou, L., Dakshanamurthy, S., Hurley, C.K., Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand. J Immunol 190 (2013), 6198–6208.
44. [44] Bari, R., Thapa, R., Bao, J., Li, Y., Zheng, J., Leung, W., KIR2DL2/2DL3-E(35) alleles are functionally stronger than-Q(35) alleles. Sci Rep, 6, 2016, 23689.
45. [45] Hilton, H.G., Guethlein, L.A., Goyos, A., Nemat-Gorgani, N., Bushnell, D.A., Norman, P.J., et al. Polymorphic HLA-C receptors balance the functional characteristics of KIR haplotypes. J Immunol 195 (2015), 3160–3170.
46. [46] Dunphy, S.E., Guinan, K.J., Chorcora, C.N., Jayaraman, J., Traherne, J.A., Trowsdale, J., et al. 2DL1, 2DL2 and 2DL3 all contribute to KIR phenotype variability on human NK cells. Genes Immun 16 (2015), 301–310.
47. [47] Brunstein, C.G., Miller, J.S., Cao, Q., McKenna, D.H., Hippen, K.L., Curtsinger, J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 117 (2011), 1061–1070.
48. [48] Sekine, T., Marin, D., Cao, K., Li, L., Mehta, P., Shaim, H., et al. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128 (2016), 297–312.
49. [49] Oevermann, L., Michaelis, S.U., Mezger, M., Lang, P., Toporski, J., Bertaina, A., et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood 124 (2014), 2744–2747.
50. [50] Galaverna, F., Guolo, F., Pende, D., Dominietto, A., Meazza, R., Falco, M., et al. Natural killer (NK) alloreactivity seems not to play a arole in preventing leukemia relapse in unmanipulated haploidentical bone marrow transplantation with post-transplant cyclophosphamide. Blood (ASH Annu Meet), 126, 2015, 2033 [abstr].
51. [51] Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005), 3051–3057.
52. [52] Bachanova, V., Cooley, S., DeFor, T.E., Verneris, M.R., Zhang, B., McKenna, D.H., et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123 (2014), 3855–3863.
53. [53] Du, J., Lopez-Verges, S., Pitcher, B.N., Johnson, J., Jung, S.H., Zhou, L., et al. CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2 (2014), 878–889.
54. [54] Rajagopalan, S., Long, E.O., KIR2DL4 (CD158d): an activation receptor for HLA-G. Front Immunol, 3, 2012, 258.
55. [55] Marie-Cardine, A., Viaud, N., Thonnart, N., Joly, R., Chanteux, S., Gauthier, L., et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res 74 (2014), 6060–6070.
56. [56] van Duin, D., Avery, R.K., Hemachandra, S., Yen-Lieberman, B., Zhang, A., Jain, A., et al. KIR and HLA interactions are associated with control of primary CMV infection in solid organ transplant recipients. Am J Transpl 14 (2014), 156–162.